TollBio Therapeutics Accelerates Development of First-in-Class Drugs for Autoimmune Diseases

Beijing TopLeader Biotech Co., Ltd. was founded in 2020 by Professor Hang Yin from the School of Pharmaceutical Sciences at Tsinghua University. The company provides innovative therapies that modulate human immune responses, addressing critical unmet needs in the global market for immunomodulatory drugs. Leveraging nearly two decades of accumulated expertise in the mechanisms of immune regulation and the development of immunomodulatory therapeutics, TopLeader Biotech utilizes cutting-edge drug discovery technologies and platforms to innovatively identify novel immune regulatory mechanisms and multiple small-molecule immunomodulators. The company has secured exclusive licenses for numerous small-molecule drug patents, with coverage spanning major pharmaceutical R&D countries and regions worldwide. It has established and is rapidly advancing multiple drug development pipelines focused on autoimmune diseases. Its lead small-molecule candidate for rheumatoid arthritis has demonstrated significantly superior efficacy and safety profiles compared to first-line clinical treatments, and clinical studies have been initiated.

Since its inception, Tuoling Botai has garnered significant attention from the industry. It has been selected into the National Key Special Project – Disruptive Technology Project Library, and has obtained certifications as a Technology-Based Small and Medium-sized Enterprise (SME) from the Ministry of Science and Technology, a Zhongguancun High-Tech Enterprise, and an Innovative SME in Beijing. The company has successfully completed its angel round and Series A financing, raising a cumulative total of nearly RMB 200 million. It has received numerous awards, including the Highest Award at the National Disruptive Technology Innovation Competition Finals organized by the Ministry of Science and Technology, the Excellent Enterprise Award at the China Innovation and Entrepreneurship Competition National Finals and the Second Prize in Beijing, TOP 150 in the Beijing Regional Competition of “Maker Beijing 2022” Innovation and Entrepreneurship Competition, the Third Prize in Beijing and the Second Prize in Haidian District at the China “Chuangyi” Innovation and Entrepreneurship Competition, the Challenge Award at the Tsinghua University President’s Cup Innovation and Entrepreneurship Competition, TOP 100 Most Innovative Medical Technology Products (Solutions) of the Year in the VB-Find Awards 2022, the “Golden Horse Award” on the 2022 China Biopharmaceutical Industry Chain Innovation List for “2022 Most Promising Startup” and “2022 Most Watched Emerging Enterprise,” and the Third Prize at the First Digital Intelligence New Industry Medical Health Entrepreneurship Competition, among many other honors.